Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

First-line Sintilimab with P-GEMOX chemotherapy in advanced Extranodal Natural Killer/T cell lymphoma (SPIRIT): a single-arm, multicenter, phase 2 trial

ABSTRACT: The addition of anti-PD-1 antibody to pegaspargase, gemcitabine and oxaliplatin (P-GEMOX) showed promising activity as first-line therapy in patients with advanced extranodal natural killer/T cell lymphoma, nasal type (ENKTL) in our previous retrospective study. Here, we assessed the clinical outcomes and multi-omics tumor profiling of sintilimab plus P-GEMOX for patients with previously untreated advanced ENKTL in this phase 2 trial.

ORGANISM(S): Homo sapiens

PROVIDER: GSE240763 | GEO | 2026/07/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification and targeting of the developmental blockade in extranodal natural killer/T cell lymphoma [RNA-seq]

Project description:Extranodal natural killer/T cell lymphoma (ENKTL) is an aggressive, rare lymphoma of natural killer (NK) cell origin with very poor clinical outcomes and no effective targeted therapies. Improved understanding of the underlying biology of the disease is critical to design more effective treatment. Here we used phenotypic and molecular profiling including epigenetic analyses to investigate how ENKTL ontogeny relates to normal NK cell development. We demonstrate that neoplastic NK cells are stably but reversibly arrested at earlier stages of NK cell maturation. Genes downregulated in the tumors that demonstrated the most epigenetic immaturity were associated with polycomb silencing along with genomic gain and overexpression of EZH2. ENKTL cells exhibited a remarkable degree of genome-wide DNA hypermethylation. Tumor-specific DNA methylation gains were associated with polycomb-marked regions, involved the silencing of hundreds of genes (many involved in NK cell development), and loss of transcription factor binding. To investigate therapeutic targeting of the epigenetic developmental blockade, we treated novel PDX models of ENKTL with the DNA hypomethylating agent, 5-azacytidine. Treatment led to reduction of DNA methylation, re-expression of NK cell developmental genes, phenotypic NK cell differentiation, and prolongation of survival. These studies lay the foundation for epigenetic-directed therapy targeting the developmental blockade in ENKTL.

2022-01-12 | GSE169644 | GEO

DNA Methylation Signatures Distinguish Extranodal NK/T-cell Lymphoma and EBV-Positive Nodal T/NK-Cell Lymphoma and Identify Prognostic Subgroups

Project description:Extranodal NK/T-cell lymphoma (ENKTL) and primary Epstein–Barr virus (EBV)-positive nodal T/NK-cell lymphoma (nodal-TNKL) are aggressive lymphomas with overlapping clinicopathologic features but distinct underlying biology. While their genomic landscapes have been increasingly defined, comparative epigenetic characterization remains limited. We performed methylated DNA immunoprecipitation sequencing (MeDIP-seq) on formalin-fixed paraffin-embedded samples from ENKTL, nodal-TNKL, ENKTL cell lines, and control tissues. ENKTL displayed extensive promoter hypermethylation associated with repression of tumor suppressor genes, lineage regulators, and lymphoid signaling genes, including LEF1 and BANK1, together with focal hypomethylation of immune- and interferon-responsive genes such as IFITM1. In contrast, nodal-TNKL showed global hypomethylation, particularly affecting cytotoxicity, immune-response, and antigen-presentation pathways; TET2-mutated cases exhibited locus-specific methylation changes consistent with impaired active demethylation. Across all samples, global DNA methylation levels correlated with genomic instability. Unsupervised clustering identified two epigenetically distinct ENKTL subgroups, one characterized by higher global methylation, TP53 loss, increased copy number alterations and loss of heterozygosity, and significantly poorer overall survival. Together, this study defines fundamental epigenetic differences between ENKTL and nodal-TNKL and links DNA methylation dynamics to genomic instability and clinical outcome, highlighting the value of methylation profiling for refined classification, risk stratification and therapeutic guidance.

2026-06-23 | GSE328647 | GEO

Identification and targeting of the developmental blockade in extranodal natural killer/T cell lymphoma [850K/EPIC DNA methylation]

2022-01-12 | GSE169643 | GEO

Envafolimab and Chidamide in combination with GEMOX as first-line treatment for advanced and metastatic biliary tract cancer (B-Enefits/SCOG-B001): A single-arm, exploratory, phase 2 trial

Project description:BTC represents a rare malignancy with unfavorable prognosis. Here we conducted a single-arm, multicenter, prospective phase Ⅱclinical study (ChiCTR2400080783) to evaluate the efficacy and safety of envafolimab and chidamide in combination with gemcitabine plus oxaliplatin (GEMOX) as first-line treatment. 10×scRNA-seq was adopted to conduct an initial exploration into the potential mechanisms underlying the efficacy of the combination regimen.

2025-07-31 | GSE301188 | GEO

Transcription profiling of natural-killer (NK) cell lymphoma to determine the disease molecular signature.

Project description:NK-cell lymphoma shares strikingly similar molecular features with a distinct subset of gamma-delta T-cell lymphoma. Gene expression profiling of NK-cell lymphoma patient samples was performed to investigate whether molecular signatures can be used to identify entities of peripheral T-cell lymphoma (PTCL) with NK-cell-like features. Gene expression profiling was performed on NK-cell maligancies to examine extranodal NK/T-cell lymphoma (ENKTL) and aggressive NK-cell leukemia (ANKL) and well-characterized cell lines of NK- and T-cell lineages to define molecular classifiers that can distinguish ENKTL from other lymphomas.

2010-03-18 | E-GEOD-19067 | biostudies-arrayexpress

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).

Project description: Not available

| S-EPMC8548511 | biostudies-literature

Gene expression of extranodal NK/T cell lymphoma II

Project description:Gene expression profiling of extranodal nasal-type NK/T cell lymphoma and other EBV-associated lymphoid proliferation disease patients was analyzed to elucidate association between JAK-STAT pathway and canonical or non-canonical PRC2/EZH2 target pathways using Illumina HumanRef-8 v3 chips.

2016-07-26 | GSE80631 | GEO

Gene expression of extranodal NK/T cell lymphoma I

2016-07-26 | GSE80629 | GEO

Gene expression of extranodal NK/T cell lymphoma II

2016-07-26 | E-GEOD-80631 | biostudies-arrayexpress